Navigation Links
Avastin Unsuccessful as Adjuvant Therapy in Setting of Stage II and III Colon Cancer but May Be Effective if Given for Longer Duration
Date:5/30/2009

Cancer researchers from the National Surgical Adjuvant Breast and Bowel Project (NSABP) and Allegheny General Hospital (AGH) in Pittsburgh reported today at the annual meeting of the American Society of Clinical Oncology (ASCO) in Orlando that use of the drug bevacizumab (Avastin) in combination with standard chemotherapy was not effective in prolonging disease-free survival (DFS) among patients with stage II and stage III colon cancer when given for one year. There is promise that using Avastin for periods longer than one year will lead to improved efficacy.

Pittsburgh, PA/Orlando, FL (Vocus) May 30, 2009 -- Cancer researchers from the National Surgical Adjuvant Breast and Bowel Project (NSABP) and Allegheny General Hospital (AGH) in Pittsburgh will report today at the annual meeting of the American Society of Clinical Oncology (ASCO) in Orlando that use of the drug bevacizumab (Avastin) in combination with standard chemotherapy was not effective in prolonging disease-free survival (DFS) in patients with stage II and stage III colon cancer when given for one year. There is promise that using Avastin for periods longer than one year will lead to improved efficacy.

Approved by the U.S. Food and Drug Administration in 2004 for the treatment of metastatic colorectal cancer and subsequently for the treatment of breast and lung cancer, Avastin is a medicine that interferes with the growth of cancer cells by inhibiting the formation of new blood vessels in cancerous tumors.

According to Norman Wolmark, M.D., principal investigator and chairman of both the NSABP and AGH’s Department of Human Oncology, the study being presented at ASCO is the first to explore use of Avastin in the adjuvant setting for patients with earlier stages of colon cancer.

Between September, 2004 and October, 2005, 2,710 patients with stage II and stage III colon cancer were randomized in the prospective study to determine whether mFolfox6 + Avastin would prolong disease free survival compared to mFolfox6 alone. Disease-free survival events were defined as first recurrence, secondary primary cancer, or death.

With a median follow-up of 36 months, the researchers found that although the addition of Avastin to mFolfox6 did not result in an overall statistically significant prolongation of DFS among study participants, there was a marked transient benefit in DFS during the one year interval that Avastin was utilized in the protocol.

“In this study, we found that Avastin substantially reduced the risk of cancer recurrence, while it was being used. The challenge moving forward is to determine how the drug can be administered in the most optimal manner, with the idea and promise that prescribing it for longer durations may improve its efficacy for patients with these stages of the disease,” Dr. Wolmark said.

Colorectal cancer is the most common cancer diagnosed in the United States. The American Cancer Society estimates that there are approximately 112,340 new cases of colon cancer and 41,420 new cases of rectal cancer diagnosed annually. Combined, they will cause about 52,180 deaths.

Determining the stage of a colon cancer diagnosis is integral to choosing the most appropriate treatment, Dr. Wolmark said. Colon cancer is classified as stage II after it moves beyond the middle layers of the colon. If colon cancer is found in at least one lymph node, it is then considered to be stage III.

Surgery remains the primary treatment for colorectal cancer while chemotherapy and/or radiotherapy may also be recommended depending on the individual patient's staging and other medical factors.

The current Avastin adjuvant treatment study was conducted by the NSABP with support from the National Cancer Institute (NCI) and a grant from Genetech, Inc. Headquartered on the campus of AGH, the NSABP is a major, NCI-funded clinical trials group that coordinates the efforts of more than 6,000 physicians, nurses and other medical professionals throughout North America, Ireland, Australia and Puerto Rico in the study of breast and bowel cancer.

###

Read the full story at http://www.prweb.com/releases/2009/05/prweb2469724.htm.


'/>"/>
Source: PRWeb
Copyright©2009 Vocus, Inc.
All rights reserved

Related medicine news :

1. Surveyed Experts Indicate That the Combination of Sutent and Taxol Has Advantages Over the Combination of Avastin and Taxol in the Treatment of Metastatic Triple-Negative Breast Cancer
2. Avastin effective at delaying brain tumor progression in recurrent disease
3. Use of Avastin and Erbitux in the Adjuvant Setting and Launches of Emerging Agents Will Drive the Colorectal Cancer Drug Market to $7.8 Billion in 2017
4. Surveyed Oncologists Indicate that Avastin has Advantages over Temodar/Temodal in Increasing Overall Survival of High-Grade Glioma
5. Avastin and Other Emerging Agents Will Drive the Glioma Drug Market to More Than $1.8 Billion in 2017
6. Genentech/Roche/Chugais Avastin Will Garner More Than 20 Percent of the Total Breast Cancer Drug Market in 2017
7. Avastin Added to Chemo Helps Women With Advanced Breast Cancer
8. Avastin Added to Chemo Helps Women With Advanced Cancer
9. Off-Label Avastin Use for Wet Macular Degeneration
10. FDA OKs Avastin for Advanced Breast Cancer
11. In Combination With FOLFOX4, the Effect of Erbitux and Avastin On Survival Rates Will Drive Prescription Decisions in the Treatment of Stage III Colon Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... ... June 25, 2016 , ... As a lifelong Southern Californian, Dr. Omkar Marathe ... from the David Geffen School of Medicine at UCLA. He trained in Internal Medicine ... his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai program where he had the ...
(Date:6/25/2016)... ... June 25, 2016 , ... Conventional wisdom preaches the benefits of moderation, whether ... latter, setting the bar too high can result in disappointment, perhaps even self-loathing. However, ... their goal. , Research from PsychTests.com reveals that behind the tendency ...
(Date:6/24/2016)... , ... June 24, 2016 , ... June 19, 2016 ... dangers associated with chronic pain and the benefits of holistic treatments, Serenity Recovery ... are suffering with Sickle Cell Disease. , Sickle Cell Disease (SCD) is a disorder ...
(Date:6/24/2016)... Fla. (PRWEB) , ... June 24, 2016 , ... Global ... Trend magazine’s 2016 Legal Elite. The attorneys chosen by their peers for this recognition ... Florida. , Seven Greenberg Traurig Shareholders received special honors as members of this year’s ...
(Date:6/24/2016)... ... 2016 , ... Topical BioMedics, Inc, makers of Topricin and MyPainAway Pain Relief Products, join The ... raise to $12 an hour by 2020 and then adjusting it yearly to increase at ... the minimum wage, assure the wage floor does not erode again, and make future increases ...
Breaking Medicine News(10 mins):
(Date:6/26/2016)... 27, 2016  VMS Rehab Systems, Inc. ( www.vmsrehabsystemsinc.com ... whatever measures required to build a strong and stable ... currently listed on the OTC Markets-pink current trading platform. ... CEO, "We are seeing an anomaly in market trading ... only by the Company, but shareholders and market players ...
(Date:6/24/2016)... , June 24, 2016  Consumers have ... and regulators/payers have placed more emphasis on patient ... patient support programs in the pharmaceutical industry have ... medications. Consequently, pharmaceutical companies are focusing on becoming ... are providing products and services that improve health. ...
(Date:6/24/2016)... , June 24, 2016  Global Blood ... biopharmaceutical company developing novel therapeutics for the treatment ... today announced the closing of its previously announced ... stock, at the public offering price of $18.75 ... offering were offered by GBT. GBT estimates net ...
Breaking Medicine Technology: